Additional Phase 3 Data Supporting OPKO's Rayaldee as a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at Kidney Week 2015
November 05, 2015 at 08:31 AM EST
OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and diagnostics company, announces that additional Phase 3 data on ...
